RWWM Inc. Makes New $796,000 Investment in Gilead Sciences, Inc. $GILD

RWWM Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 7,169 shares of the biopharmaceutical company’s stock, valued at approximately $796,000. Gilead Sciences makes up 0.1% of RWWM Inc.’s holdings, making the stock its 23rd biggest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Invesco Ltd. increased its position in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Finally, Amundi increased its position in Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wolfe Research lifted their price target on shares of Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Daiwa Capital Markets raised their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $136.36.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $141.95 on Friday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $142.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market capitalization of $176.11 billion, a price-to-earnings ratio of 22.01, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The firm’s fifty day moving average price is $125.36 and its 200 day moving average price is $119.59.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the firm earned $2.02 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 257,397 shares of company stock valued at $33,385,512 in the last three months. 0.27% of the stock is currently owned by company insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.